Zoetis Inc. (NYSE:ZTS) Shares Acquired by Marshall Financial Group LLC

Marshall Financial Group LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 6.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 9,944 shares of the company’s stock after acquiring an additional 587 shares during the quarter. Marshall Financial Group LLC’s holdings in Zoetis were worth $1,637,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Mission Wealth Management LP boosted its position in Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. raised its stake in shares of Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after acquiring an additional 62 shares during the last quarter. HUB Investment Partners LLC boosted its holdings in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC grew its position in Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock worth $68,000 after acquiring an additional 64 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its position in Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after acquiring an additional 65 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on ZTS shares. UBS Group reduced their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $212.75.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president now owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock opened at $168.64 on Friday. The firm’s 50 day moving average price is $158.26 and its two-hundred day moving average price is $164.09. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market cap of $75.08 billion, a PE ratio of 30.83, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the firm posted $1.38 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.19%. The ex-dividend date is Friday, July 18th. Zoetis’s payout ratio is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.